What is IGeneX?
Headquartered in Milpitas, California, IGeneX operates at the intersection of clinical diagnostics and infectious disease management. The company has carved out a significant niche by focusing exclusively on the detection of Lyme disease and a broad spectrum of tick-borne illnesses. Through a sophisticated model that provides specialized collection kits directly to patients and medical practitioners, IGeneX facilitates precise pathogen identification. Their reputation is built upon rigorous testing methodologies that address the diagnostic challenges inherent in chronic and acute tick-borne conditions, making them a critical partner for clinicians navigating complex patient symptoms. The firm serves a diverse ecosystem, ranging from individual patients seeking clarity to large-scale employers and healthcare networks requiring reliable diagnostic data.
How much funding has IGeneX raised?
IGeneX has raised a total of $1.2M across 2 funding rounds:
Debt
$350K
Debt
$870K
Debt (2020): $350K with participation from PPP
Debt (2021): $870K led by PPP
Key Investors in IGeneX
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for IGeneX?
With the recent influx of capital, IGeneX is well-positioned to scale its operational capacity and enhance its diagnostic throughput. The company's trajectory suggests a focus on expanding its laboratory footprint and potentially integrating advanced molecular diagnostic technologies to further improve sensitivity and specificity in pathogen detection. As the demand for specialized diagnostic services grows, IGeneX is likely to prioritize strategic partnerships with healthcare systems to streamline the testing workflow. This phase of growth is expected to reinforce the company's leadership in the tick-borne disease market, enabling it to address the evolving needs of the medical community while maintaining the high standards of accuracy that define its brand identity.
See full IGeneX company page
